Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
|Videos|June 30, 2021
Medical World News® Deep Dive: Expert Talks FDA Approval of Amivantamab to Treat NSCLC With EGFR Exon 20 Insertion Mutations
Author(s)Matthew Fowler
Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Advertisement
In this episode of Deep Dive from the
Sabari detailed the challenges of treating tumors with this mutation and compared amivantamab with the other systemic therapy options in this setting. He also discusses what the future might have in store for amivantamab in this specific disease.
Advertisement
Related to this article
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
4
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
5